Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 15/2013

01.10.2013 | Editorial

Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?

verfasst von: Andrew J. Krentz, Marcus Hompesch

Erschienen in: Drugs | Ausgabe 15/2013

Einloggen, um Zugang zu erhalten

Excerpt

Excess adiposity, arising from a chronic imbalance of energy intake relative to expenditure, is regarded as a hallmark of type 2 diabetes. It is well established that whole-body insulin resistance results from the acquisition of surplus adipose tissue mass. In turn, insulin resistance is implicated in the deleterious cardiometabolic profile that is characteristic of type 2 diabetes [1]. Voluntary decreases in body fat mass lead to improvements in carbohydrate and lipid metabolism together with reductions in blood pressure and markers of inflammation [1, 2]. Accordingly, current international treatment guidelines for type 2 diabetes advocate reducing hyperglycemia using non-pharmacological means wherever possible [3, 4]. …
Literatur
1.
Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27:2067–73.PubMedCrossRef
2.
3.
4.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.PubMedCrossRef
5.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–36.PubMed
6.
Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.PubMedCrossRef
7.
Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11:361–71.PubMedCrossRef
8.
Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care. 2005;28:942–9.PubMedCrossRef
9.
Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660–72.PubMedCrossRef
10.
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.PubMedCrossRef
11.
Astrup AV, Oppert J-M, Peterson CA. Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine/topiramate treatment in overweight/obese subjects with type 2 diabetes. Diabetologia 2012;55(suppl 1):S48.
12.
Redman LM, Ravussin E. Lorcaserin for the treatment of obesity. Drugs Today. 2010;46:901–10.PubMedCrossRef
13.
Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin. 2013;29:839–48.
14.
Hoy SM. Lorcaserin: a review of its use in chronic weight management. Drugs. 2013;73(5):463–73.
15.
Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Dev Ther. 2010;5:1–7.
16.
Gallwitz B. Novel oral anti-obesity agents: new perspectives with lorcaserin? Drugs. 2013;73:393–5.PubMedCrossRef
17.
O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.PubMedCrossRef
18.
Kenkre J, Tan T, Bloom S. Treating the obese diabetic. Expert Rev Clin Pharmacol. 2013;6:171–83.PubMedCrossRef
19.
Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity. 2009;17:494–503.PubMedCrossRef
20.
Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14(5):383–92.
21.
22.
Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience. N Engl J Med. Epub 2 Sep 2013
23.
Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540–59.PubMedCrossRef
24.
Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2013;36:1779–88.PubMedCrossRef
Metadaten
Titel
Targeting Hyperglycaemia with Anti-Obesity Drugs: Time for a Paradigm Shift?
verfasst von
Andrew J. Krentz
Marcus Hompesch
Publikationsdatum
01.10.2013
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 15/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0123-2

Weitere Artikel der Ausgabe 15/2013

Drugs 15/2013 Zur Ausgabe

Adis Drug Evaluation

Fidaxomicin: A Review of Its Use in Patients with Clostridium difficile Infection

Adis Drug Evaluation

Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer

Therapy in Practice

Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations

Systematic Review

A Systematic Review of Pharmacological Pain Management in Multiple Sclerosis

Review Article

Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

Leading Article

β-Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives